US2017233468A1PendingUtilityA1

Il-17 antagonist antibodies

52
Assignee: OREGA BIOTECHPriority: Jun 25, 2012Filed: Apr 20, 2017Published: Aug 17, 2017
Est. expiryJun 25, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Gilles AlbericiJeremy BastidArmand BensussanNathalie BonnefoyJean-Francois Eliaou
G01N 33/6869C07K 2317/626C07K 2317/624C07K 2317/622C07K 2317/56C07K 2317/24C07K 2317/21A61K 2039/505G01N 33/57515C07K 2317/92C07K 2317/76C07K 2317/55C07K 2317/54C07K 2317/34C07K 2317/33C12N 15/09A61K 39/395C12P 21/02C12P 21/00C07K 16/244
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated interleukin-17 (IL-17) antibody which binds, as a major epitope, an epitope consisting of a sequence of the human IL-17A as set forth in SEQ ID NO: 8.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.